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1.  Introduction  
  
 This thesis represents a collection of several papers [A1-A7], in which the main 
research area is, in one way or another, linked to problems and questions originating from the 
development of voice and speech disorders in the course of Parkinson’s disease (PD). Using 
innovative methods of acoustic analysis, speech signal processing techniques, and advanced 
statistics, the present thesis strives to contribute to the greater understanding of the role of 
speech impairment in PD. 
 Individual papers are focused on (a) development of acoustic measurement methods 
with respect to their automatic assessment and characterization of the specific signs of the 
PD-related vocal impairment from the early stages of disease [A1], (b) investigation of the 
feasibility of acoustic measures for the identification of voice and speech disorders in early 
PD, using a simple screening test [A2], (c) description of the vowel characteristic in two 
groups of untreated parkinsonian speakers across different types of speech tasks [A3], (d) 
design of a novel change-point detection algorithm for application in voice pathology [A4], 
and (e) the longitudinal effect of pharmacotherapy treatment on key dimensions of speech 
using quantitative acoustic analysis in a group of de novo PD patients and one to two years 
after introduction of therapy [A5]. Furthermore, papers [A2, A3, A5] investigate possible 
relationships between PD speech and motor symptoms to provide more insights into 
understanding the pathophysiological mechanisms responsible for the progression of 
parkinsonian speech impairment. In addition, papers [A6, A7] focus on the design of 
simulation models for educational purposes and general reflections on the physiological 
principles of various diseases. 
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2.  State of the Art  
 
Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by the 
progressive lost of dopaminergic neurons in the substantia nigra [1]. PD is associated with 
dopamine deficiency and other affections of the brain neuromediator systems, and is 
responsible for a variety of motor and non-motor deficits.  
PD is the second most common neurodegenerative disorder after Alzheimer’s disease, 
with prevalence exceeding 100/100,000 [2, 3]. Previous research suggests that PD usually 
affects people after the age of 50 years [4]. Only 10% of patients with PD report symptoms 
before the age of 40 years [5]. Moreover, PD is estimated to affect 1.6% of persons over the 
age of 65 years [2]. Given the fact that age is the most important factor for onset of PD [6], 
and that the population is growing older, the statistics for the number of affected persons are 
expected to increase in the near future [7]. Currently, there is no available causal cure, 
although medication, including neuro-pharmacological and neuro-surgical methods, offers 
alleviation of some symptoms, especially in the early stages of the disease. Thus, early 
diagnosis has a vital role in improving the patients’ lives and will be crucial when treatment 
become feasible [8].  
In addition to the main motor symptoms such as bradykinesia, rigidity, resting tremor, 
and postural instability, it is estimated that up to 90% of patients with PD develop hypokinetic 
dysarthria in the course of their illness. [9-12]. This alteration of speech may also be one of 
the earliest indicators of the disease [13, 14]. Acoustical analysis of speech might therefore 
provide useful biomarkers for the early diagnosis of PD [15], for possible remote monitoring 
of patients [16], but above all, for providing important feedback in voice treatment for 
clinicians or patients themselves. For adult subjects, methods allowing the assessment of the 
speech performance and acoustic feedback tests can be essential for stimulating motivation 
and willingness for speech therapy. In other words, acoustic measurements can improve the 
individual treatment [17], and therefore partially alleviate the inconvenience and cost of 
physical visits [18]. Moreover, voice measurement is non-invasive, cheap and simple to 
administer. 
The most prominent signs of parkinsonian speech relate to phonatory, articulatory, and 
prosodic deviations, and are characterized by abnormal voice quality, articulatory 
imprecision, reduced variability of pitch and loudness, variable rate, and disfluent speech 
behaviour [10, 13]. Many voice and speech tasks have been devised to assess the extent of 
these symptoms, including vocal recordings of sustained phonations, rapid syllable 
repetitions, and variable reading of sentences or freely spoken monologues. The speech 
signals are then commonly analyzed using several traditional measurement methods, which 
include sound pressure level, fundamental frequency, formant frequencies, speech rate, 
rhythm, and others [19]. A number of previous studies have used these methods to separate 
PD sufferers from healthy participants, indicating that these standards could be useful 
measures in assessing the extent of vocal impairment, note for example [20-22]. Recently, 
several studies have appeared making use of innovative methods for voice and speech 
disorders detection [23-27]. However, there are practical limitations of effort and cost-
outcome associated with obtaining and verifying each of the methods, which are dependent on 
a specific and often unavailable speech sample. Therefore, what is most needed is the finding 
of reliable methods for characterization of complex aspects of speech production in PD. 
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In reality, however, the reliability and robustness of acoustic measurement methods is 
impeded by several confounding effects associated with characteristics of the subjects and 
technology. First, issues related to personal characteristics include inter-speaker variability 
(gender, age), intra-speaker variability (repetition of speech task), variability in evolution of 
speech disorders across individual speakers, and variability in the quality of healthy speech 
(breathy voice, speech rate, hesitations, mumbling, and others). Second, issues related to 
technology include environmental noise, choice of microphone (type, distance), robustness of 
the algorithms, and the choice of speech material that best depicts the abnormalities. Thus the 
measurement methods performed on various vocal recordings should be chosen, as much as 
possible, with an eye to these confusing and in many cases even counteractive effects.  
 Another relevant and often overlooked factor in determining the extent of PD speech 
impairment is the dependence on the stage of disease. The progressive decline of several 
speech characteristics in the course of PD has already been reported [28-31]. Although there 
are many previous studies using several measures and vocal tasks for assessment of PD-
related voice and speech disorders in various stages of the disease, little effort was given to 
investigation of the extent of vocal impairment and the suitability of acoustic measures in 
early stages of PD, before and after starting dopaminergic pharmacotherapy.  
 While the beneficial effect of dopaminergic therapy on principal motor symptoms in 
PD has been well documented, its effect on speech remains unclear. Generally, severity of 
hypokinetic dysarthria is believed to increase with longer duration of disease and increased 
severity of limb impairment [32]. In other words, the speech dysfunction in the course of PD 
is hypothesized to be the result of rigor and hypokinesia of the vocal tract. Therefore, one 
could expect improvement in speech performances owing to the positive response to 
dopaminergic therapy. However, with respect to previous literature, the effect of 
dopaminergic stimulation on overall speech parameters remains inconclusive with mixed and 
contradictory findings. Whereas several researchers have reported certain beneficial effects of 
dopaminergic therapy on various aspects of speech production [19, 33-36], others have not 
found changes in speech parameters and/or overall intelligibility under pharmacotherapy [37-
41]. In overall, little correspondence has been found between the severity of limb and the 
speech symptoms [32].   
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3.  Aims of the Doctoral Thesis  
 
The doctoral thesis has the following interrelated goals: 
 
(1) To identify PD-related acoustic signatures for the major part of traditional 
clinically used measurement methods with respect to their automatic assessment. 
(2) To design new automatic measurement methods of articulation. 
(3) To design a novel robust detector of abrupt spectral changes. 
(4) On the basis of methods from points 1 through 3, using the designed evaluation 
criteria, to determine whether the voice and speech disorder are present from early 
stages of PD before starting dopaminergic pharmacotherapy. 
(5) On the basis of methods from points 1 through 4, to ascertain the specific 
characteristics of PD-related vocal impairment. 
(6) On the basis of previous findings from points 1 through 5, to design a quick vocal 
test in order to be gender independent, represent all aspects of speech, reduce time 
required for investigation, and provide reliable assessment in practice.   
(7) On the basis of methods from point 6, to test and find the optimal combination of 
acoustic measurements for separating untreated PD from healthy participants. 
(8) To describe vowel articulation using formant characteristics in parkinsonian 
speakers when compared to normal healthy speakers. 
(9) To investigate the feasibility of formant measures in vowel articulation across 
different speaking tasks and to point out which tasks are most sensitive to PD. 
(10) On the basis of previous findings from points 1 through 9, using the designed 
evaluation criteria, to investigate the longitudinal effect of treatment on key 
dimensions of speech in a group of de novo PD patients and after introduction of 
therapy.  
(11) In general, to find possible relationships between PD speech and motor symptoms 
to provide more insights into understanding of pathophysiological mechanisms 
responsible for the progression of parkinsonian speech impairment. 
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4. Working Methods  
 
4.1. Subjects 
 
From 2007 to 2010, 24 Czech native-speaking participants (20 men and 4 women) 
fulfilling the diagnostic criteria for PD were recruited for this study. All PD patients were first 
examined shortly after the diagnosis was made, before symptomatic treatment was started. 
After optimization of the treatment consisting mostly of levodopa and/or a dopamine agonist, 
19 patients (16 men and 3 women) were also re-tested after one to two years in their best on-
state according to the same protocol. In addition, 23 volunteers (16 men and 7 women) with 
no history of neurological or communication disorders were included as healthy controls 
(HC). The study was approved by the local ethics committee. All participants provided 
written informed consent. 
 
4.2. Data and Recording 
 
The speech data was recorded in a quiet room with a low ambient noise level using an 
external condenser microphone placed at approximately 15 cm from the mouth and coupled to 
a Panasonic NV-GS 180 video camera. The voice signals were recorded directly to the 
computer, sampled at 48 kHz with 16-bit resolution. The vocal tasks used in this study ranged 
from producing isolated vowels to reading short sentences and producing a short, spontaneous 
monologue about a given subject (see Table 1). 
 
 
 
Task code Speech data 
[VT1] Sustained phonation of /i/ at a comfortable pitch and loudness as constant and long as possible, at least  5-sec. 
This task was performed on one breath. 
[VT2] Rapid steady /pa/-/ta/-/ka/ syllables repetition as constant and long as possible, repeated at least 5-times. 
This task was performed on one breath. 
[VT3] Monologue, at least approx. 90-sec. The participants were generally instructed to speak about:  
what they did  current day or last week, their interests, their job, or their family. 
[VT4] Reading the same standard phonetically non-balanced text of 136 words. 
[VT5] Approximately 5-sec sustained vowels of /a/, /i/, /u/ at a comfortable pitch and loudness. 
The vowels were performed on one breath.  
[VT6] Reading the same text containing 8 variable sentences of 71 words with varied stress patterns on 10 indicated 
words. 
[VT7] Reading 10 sentences according specific emotions in a comfortable voice in response to an emotionally neutral  
sentence including excitement, sadness, confusion, fear, boredom, anger, bitterness, disappointment, wonder, 
and enjoyment. 
[VT8] Rhythmically read text containing 8 rhymes of 34 words following the example set by the examinator. 
[VT9] Five-time repetition of the 8 words phrase. 
 
Table 1: List of the vocal tasks. 
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4.3. Acoustic Measurements 
 
In the course of the thesis, we have designed a number of traditional and novel metrics 
used for speech analyses (see Table 2). These measurements of the PD speech can be 
associated with several dimensions, where: phonation represents the vibration of the vocal 
folds to create sound, articulation is the modification of the position and shape of speech 
organs (tongue, lips, jaw) in the creation of sound, prosody represents the variation in 
loudness, pitch, and timing accompanying natural speech, and respiration refers to the action 
of the respiratory apparatus during exhalation, providing a continuous stream of air with 
sufficient volume and pressure to initiate phonation.  
Feature Vocal task Speech subsystem Description 
F0  SD [VT1] Phonation Standard deviation of fundamental frequency (F0) converted to semitone scale,  
[VT3,4,6,7] Prosody representing the variations of vibration rate of vocal folds. 
Jitter [VT1] Phonation Frequency perturbation, representing the extent of variation of the voice range.  
(%) Jitter is defined as the variability of the fundamental frequency of speech from  
one cycle to the next.  
Shimmer [VT1] Phonation Amplitude perturbation, representing rough speech. Shimmer is defined as the 
(%) sequence of maximum extent of the signal amplitude within each vocal cycle. 
NHR  [VT1] Phonation Noise-to-Harmonics-Ratio, the amplitude of noise relative to tonal 
(%)  components. 
HNR [VT1] Phonation Harmonics-to-Noise-Ratio, the amplitude of tonal relative to noise  
(dB) components. 
Percent pause time  [VT3,4] Prosody The percent change from the unedited sample length to the edited sample  
(%) length. 
Articulation rate  [VT4] Prosody The number of syllables produced per second, after removing silence period  
(syll/s) exceeding 60 ms. 
Number of pauses  [VT3,4] Prosody The number of all pauses compared to total time duration, after removing  
(pauses/s) silence period not lasting more than 60 ms. 
DDK rate  [VT2] Articulation The number of /pa/-/ta/-/ka/  syllable vocalizations per second. 
(syll/s) 
DDK regularity [VT2] Articulation The degree of /pa/-/ta/-/ka/ syllable vocalizations rate variations 
(-) in the period. 
Intensity  SD [VT3,4,6] Prosody Variations of average squared amplitude within a predefined time segment  
(dB) ("energy") after removing silence period exceeding 60 ms. 
Rhythm [VT8] Prosody Measurement of ability to reproduce perceived rhythm through dynamic time 
(-) warping.  
SPLD [VT2] Respiration Robust Relative Intensity Slope, the robust linear regression of energy. 
(dB/s) 
SDCV [VT2] Articulation Spectral Distance Change Variations, the variations of spectral distance 
(-) changes in signal spectrum. 
RFPC  [VT2] Articulation Robust Formant Periodicity Correlations, the first autocorrelation  
(-) coefficient of F2 contour. 
VSA [VT3-5,9] Articulation Quantitative measure which involves plotting the three corner vowels in  
(Hz2) F1/F2 plane. 
FCR [VT3-5,9] Articulation Formant Centralization Ratio, measurement of vowel articulation based on F1 
(-) and F2 formant frequencies of corner vowels (/a/, /i/, and /u/). 
F2i/F2u [VT3-5,9] Articulation Measurement of vowel articulation based on ratio of F2 frequencies of corner  
(-) vowels /i/ and /u/.  
RPDE [VT1] Phonation Recurrence Period Density Entropy, representing an extension of the concept of  
(-) periodicity. 
PPE [VT1] Phonation Pitch Period Entropy, representing the inefficiency of voice frequency control. 
(-) 
MPT [VT1] Phonation Maximum Phonation Time, respiratory parameter, representing aerodynamic  
(s) efficiency. 
PDW [VT3,4] Prosody Percent Disfluent Words, representing speech fluency. 
(%)       
 
Table 2: Overview of measurement methods used as a features applied to acoustic signals. 
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4.4. Statistics 
 
To assess the extent of vocal impairment in PD patients, we have designed the 
classification based on the both traditional and novel statistics. The Kolmogorov-Smirnov test 
for independent samples was used to test for normality of the distribution of the data. Analysis 
of variance with post hoc Bonferroni adjustment was used to assess differences between the 
groups. The Pearson and Spearman correlation analysis was used to assess the strength of the 
relationships between individual measures. For characterization of speech disorders in PD 
[A1], differentiation of parkinsonian from healthy speakers [A2], and evaluation of treatment 
effect [A5], we have used advanced classification methods based upon Gaussian kernel 
density, Wald task, support vector machine, and minimal detectable change.  
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5. Results 
 
5.1. Voice and Speech Characteristics in PD 
 
Table 3 lists the general results of acoustic analysis with statistical significances across 
all the studies [A1-A5].  The results are presented according to the main speech 
characteristics, including phonation, articulation, and prosody.  
 Statistical significances were found in most measures of phonation. Additional noise 
captured by ratios of noise-to-harmonics can indicate incomplete vocal fold closure and 
incorrect vocal fold oscillation. The noise in speech can be also generated by turbulent airflow 
through the vocal fold. Significant deficits in phonation due to PD may be perceptually 
interpreted as poor voice quality and described in terms like hoarse, harsh, breathy and rough 
voice, or even voice tremor. 
 From traditional articulation measures based upon the DDK task, only the DDK rate 
contains significant differences between both groups. On the other hand, all novel measures 
performed on the DDK task shown statistically significant differences between groups, which 
can indicate reduced movement of orofacial muscles. In many patients with PD, intensity 
defects develop in instances of rapid articulation. The reduced intensity variations can be 
caused by occlusive weakening. As an example, voiceless occlusives, which are normally 
associated with a silent gap, tend to exhibit energy during the silent gap. This energy can be 
caused by turbulent noise generated at the site of oral constriction because of an incomplete 
occlusion, or voicing energy which occurs as a result of poor coordination between laryngeal 
and supralaryngeal gestures. The results of sound pressure level decline show that PD patients 
have a lower ability to maintain the intensity level, which can be caused by weakness in the 
production of stable airflow from the lungs. The higher number peaks captured by spectral 
distance change variation can be associated with greater spectral changes which represent a 
greater clarity of articulation. The rate and similarity of tongue movement are well 
represented by the measure of formant periodicity correlation where the higher periodicity in 
the obtained F2 sequence represents better articulation accuracy of tongue.  
In the speech subsystem of prosody, reduced variation of melody and decreased 
intensity variation has been found to be the most prominent sign of parkinsonian speech. This 
situation can be caused by changed laryngeal tension, decreased breath support, and decreased 
range of motions. The patients with PD show a lower ability to reproduce perceived rhythm. 
From pause characteristics, only the measurements of number of pauses show significant 
differences between groups. This can be indicated by breathiness and starting time of the 
tongue movement. The persons with PD have not shown significant differences in the 
articulation rate and speech disfluency compared to HC, which can be caused due to higher 
inter-individual variability.  
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    Subjects       Difference 
Measurement PD   HC   between 
    Mean (SD) Mean (SD) groups 
Phonation 
 [VT1] Sustained phonation 
   F0 SD (semitones) 0.46 0.49 0.35 0.23 Not significant 
   Jitter (%) 1.53 1.37 0.65 0.78 p < 0.01 
   Shimmer (%) 7.51 4.97 2.72 2.27 p < 0.001 
   NHR (-) 0.16 0.27 0.02 0.04 p < 0.01 
   HNR (dB) 16.01 7.36 24.02 5.61 p < 0.001 
   RPDE (-) 0.32 0.08 0.27 0.06 Not significant 
   PPE (-) 0.48 0.28 0.26 0.12 p < 0.01 
   MPT (s) 20.84 8.81 22.00 6.88 Not significant 
Articulation 
 [VT2] DDK task 
   DDK rate (syll/s) 6.22 0.63 7.16 0.73 p < 0.001 
   DDK regularity (-) 0.54 0.58 0.67 0.36 Not significant 
   Intensity SD (dB) 7.54 1.52 10.99 1.96 p < 0.001 
   SPLD (dB/s) 2.75 1.51 1.16 1.12 p < 0.001 
   RFPC (-) 0.46 0.17 0.60 0.09 p < 0.01 
   SDCV (-) 0.14 0.03 0.18 0.03 p < 0.001 
 [VT3] Monologue 
   VSA (Hz2)  121881 31508 154205 41470 p < 0.05 
   F2i/F2u (-) 2.10 0.20 2.38 0.25 p < 0.05 
   FCR (-) 0.86 0.05 0.92 0.06 p < 0.05 
 [VT4] Reading text 
   VSA (Hz2)  118689 43093 142690 40859 Not significant 
   F2i/F2u (-) 2.28 0.31 2.52 0.28 p < 0.05 
   FCR (-) 0.87 0.07 0.91 0.06 Not significant 
 [VT5] Sustained vowels 
   VSA (Hz2)  225643 73531 268276 75894 Not significant 
   F2i/F2u (-) 2.88 0.32 3.05 0.40 Not significant 
   FCR (-) 1.10 0.07 1.15 0.10 Not significant 
 [VT9] Sentence repetition 
   VSA (Hz2)  116954 54533 173175 60062 p < 0.05 
   F2i/F2u (-) 1.96 0.29 2.31 0.37 p < 0.05 
   FCR (-) 0.84 0.07 0.91 0.08 p < 0.05 
Prosody 
 [VT3] Monologue 
   F0 SD (semitones) 1.53 0.32 2.44 0.65 p < 0.001 
   Intensity SD (dB) 7.05 1.41 8.75 1.51 p < 0.001 
   Percent pause time (%) 0.32 0.03 0.31 0.03 Not significant 
   Number of pauses (pauses/s) 3.04 0.83 3.86 0.69 p < 0.01 
   PDW (%) 3.89 2.44 1.62 0.37 Not significant 
 [VT4] Reading text 
   F0 SD (semitones) 1.71 0.66 2.48 0.56 p < 0.001 
   Intensity SD (dB) 5.93 1.05 7.55 1.62 p < 0.001 
   Percent pause time (%) 0.30 0.02 0.29 0.02 Not significant 
   Articulation rate (syll/s) 6.09 0.78 6.09 0.84 Not significant 
   Number of pauses (pauses/s) 3.29 0.67 3.98 0.51 p < 0.01 
   PDW (%) 2.34 1.61 1.50 1.07 Not significant 
 [VT6] Stress patterns 
   F0 SD (semitones) 2.06 0.81 2.78 0.62 p < 0.01 
   Intensity SD (dB) 6.40 1.07 7.84 1.97 p < 0.01 
 [VT7] Emotional sentences 
   F0 SD (semitones) 2.59 0.74 3.82 0.56 p < 0.001 
 [VT8] Rhythmic text 
   Rhythm (-)   2.65 0.55 2.27 0.28 p < 0.01 
 
Table 3: List of all measures with mean values, SD values, and statistical significances. 
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5.2. Objectification of Hypokinetic Dysarthria 
 
On the basis of statistics presented in [A1], we were able to show that the patterns of 
speech performance are spread through all speech dimensions only in the HC group, while the 
parkinsonian speech defects differ individually in various characteristics including phonation, 
articulation, and prosody. As can be seen in Figure 1, the vocal impairment in early stage of 
the PD in the view of all speech dimensions is rather individual.  From all PD patients, 78% 
are affected. We have found phonatory deficits in 26% cases, lower ability of articulation in 
39% cases, and certain problems with prosody in 60% cases of PD patients. Deficits in all 
speech characteristics were found only in 13% of people with PD. Approximately 26% of PD 
subjects show single deficits only in prosody, 17% PD patients only in articulation, none in 
phonation, and 21% in some combination of two speech characteristics. It is important to keep 
in mind that the speech measurements can be partially interconnected in all speech 
dimensions. Hence the speech impairment in early stages of PD might be considered as the 
total of speech defects in various speech characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Details of affected speech dimensions in PD. 
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5.3. Differentiation of Parkinsonian from Healthy Speakers 
  
On the basis of the quick vocal test and the prediction model presented in [A2], we 
have obtained the best classification performance of approximately 85% in the combination of 
4 measures including NHR, SPLD, RFPC, and F0 SD. Each of these measures represents one 
important speech subsystem related to PD: NHR shows abnormalities in phonation, SPLD 
represents an impaired ability to maintain appropriate intensity level in respiration, RFPC 
measures deficits of speech organ movement during articulation, and finally, the measure of 
F0 SD can elicit deficits in prosody. The classification performance using the subset of all 
measurements was 82%. From individual measures, F0 SD obtained the best classification 
accuracy of 81%. The maximal correct overall classification accuracy was 76% using only 
sustained phonation, and 71% using only the DDK task. Figure 2 summarizes the procedure 
and results of the quick vocal test that was employed to evaluate voice and speech disorders in 
a group of patients with unmedicated PD in comparison to healthy people. According to these 
results, the deficits in speech prosody appear to contain the greatest amount of information in 
assessment of PD-related vocal impairment before starting dopaminergic pharmacotherapy. 
 
SPEECH SUBSYSTEMS MEASURESEVALUATION
SUBJECT
Phonation ↔ NHR [VT1]
Respiration ↔ SPLD [VT2]
Articulation ↔ RFPC [VT2]
Prosody  ↔ F0 SD [VT3]
Person  in early sta-
ge of Parkinson‘s 
disease speaks to 
microphone
Correct overall rate of 85.02 %
Speech signal
processing
SV
M
-b
ui
ld
 
m
od
el
VOCAL TASKS
[VT1] Sustained phonation
(at least 5 s; approximately 15 s)
[VT2] Fast syllables repetition
(at least 5-times /pa/-/ta/-/ka/ repetition)
[VT3] Running speech
(about 170 words; approximately 80 s)
True positive rate of 82.78 %
(the number of Parkinsonians correctly 
classifi ed)
True negative rate of 87.56 %
(the number of healthy people correctly 
classifi ed)
R
ec
or
di
ng
 
Figure 2: Schematic diagram depicting the recording of the PD patient’s speech signals 
through the quick vocal test. Signals are subsequently calculated using speech signal 
processing algorithms and evaluated using the SVM-based model which can predict the 
PD-related voice and speech disorders. 
 
12 
 
5.4. Vowel Articulation in PD and Comparison between Speaking Tasks 
 
On the basis of the findings presented in [A3], speakers with mild dysarthria have 
reduced VSA and manifest abnormalities in formant centralizations represented by F2i/F2u 
and FCR. In addition, the type of speaking task can exert significant influence on 
parkinsonian speech performance. In comparison to HC group, the parkinsonian group 
showed significant differences using the speaking task of sentence repetition, reading text, 
and monologue. The resulting speech performances show that the speaking task of sentence 
repetition was more closely associated with reading passage, and reading passage was more 
closely associated with monologue. However, the sustained phonation was found to be an 
inappropriate speaking task for assessment of complex vowel articulation. The atypical 
changes in F2 of /i/ and /u/ vowel extracted from the speaking task of monologue were best 
able to predict vowel impairment starting from the early stages of PD. 
 
5.5. Novel Approach to Measure of Spectral Changes 
 
A novel changepoint detection algorithm has been designed for automatic acoustic 
assessment of voice pathology with respect to relevance of changes in spectral discontinuity 
and the spectral envelope of the speech signal [A4]. Using developed detector, the principle of 
designed articulation measures are then based upon assumption that dysarthria-related 
imprecise articulation is among others demonstrated by lower spectral changes. Our findings 
confirm that people with hypokinetic dysarthria can be distinguished from healthy speakers 
on the basis of spectral changes where the degree of spectral change has been shown to be 
higher during healthy speech. In contrast to measures of articulation, we have also found that 
the variability of distances between individual spectral changes was significantly increased as 
a consequence of the higher degree of disfluency.  
 
5.6. Evaluation of Treatment Effect 
 
On the basis of innovative statistics presented in [A5], individual speech performances 
improved in most patients after the introduction of dopaminergic treatment. Generally, 
treatment-related changes differed individually across various aspects of speech. Most 
patients showed improvement in loudness of speech (according to the Intensity SD for 
reading text and monologue) and quality of voice (according to the jitter, shimmer, HNR, 
RPDE, PPE), followed by improvement in intonation variability (according to the F0 SD for 
reading text and monologue) and vowel articulation (according to the VAI, F2i/F2u for 
reading text and monologue). In measures of consonant-to-vowel accuracy (according to the 
RFPC, SDCV), only the SDCV indicated improved speech in PD. Additionally, speech 
performances in measures of the sustained phonation time (according to the MPT) and 
disfluency (PDW for reading text and monologue) were maintained or changed individually. 
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5.7. Relationships between PD Speech and Motor Symptoms 
 
In order to provide more insights into the understanding of the pathophysiological 
mechanisms responsible for reduced speech performance due to PD, several experiments were 
performed to find possible relationships between parkinsonian speech and motor symptoms 
[A2, A3, A5]. From the correlations between single speech and motor parameters according 
to the Unified PD Rating Scale III, statistically significant relationships were mainly found 
between several measures of phonation and articulation and subscores of bradykinesia and 
rigidity. Nevertheless, after the introduction of dopaminergic treatment, we observed a 
significant correlation between change in the bradykinesia and rigidity subscore and in the 
measures of vowel articulation. In addition, there was a significant correlation between 
changes in the rigidity subscore and the measure of intonation variability. Fig. 3 summarizes 
the overall speech changes associated with the introduction of therapy, and the relationship 
between PD speech and motor manifestations. 
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Figure 3: Schematic diagram depicting the speech changes after the introduction of 
treatment and relationships between speech and motor symptoms. 
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6. Conclusions 
 
Using innovative methods of acoustic analysis in de novo PD patients, this thesis 
strives to provide more insights into progression of parkinsonian speech and voice disorders. 
We believe that our designed acoustic methods as well as general findings will be important 
for several reasons. It may be helpful in diagnosis of the disease, classifying the severity of 
disease, monitoring treatment, providing feedback in therapy, and support for therapists in the 
evaluation.  
 In the course of this thesis, we collected a unique sample of patients prior to 
undergoing pharmaceutical treatment. Most of these patients were also re-tested one to two 
years after the introduction of dopaminergic therapy. Our main finding is that approximately 
80-90% of early untreated PD subjects show some form of vocal impairment. The 
predominant patterns of speech deficits in untreated patients include impaired phonation, 
inaccurate articulation, reduced pitch and loudness variability, and other prosodic 
disturbances. Although a number of researchers believe that the most salient features of PD 
speech are related to phonatory and articulatory impairment, the prosody of speech appears to 
be the most affected speech subsystem of the hypokinetic dysarthria in early stages of PD. 
Moreover, the specific parkinsonian voice and speech defects were found to differ 
individually in various dimensions including respiration, phonation, articulation, and prosody. 
These findings also show that persons in early stages of PD may not demonstrate a voice 
sufficiently impaired as to differentiate speech production from the wider norm of healthy 
people. In addition to these results, we have found that reduced articulatory movements are 
developed along with the progression of PD-related dysarthria. The alteration in the 
articulation of the vowels /i/ and /u/ are most sensitive in distinguishing parkinsonian from 
healthy speakers and are acoustically notable even in PD speakers with no perceptible 
dysarthria. Finally, after introduction of pharmacotherapy, PD speech performances were 
improved mainly in the loudness of speech, quality of voice, pitch variability, and 
articulation. Notably, hypokinetic articulation and pitch variability in spontaneous speech 
appeared as a corollary of principal motor symptoms of PD, reflecting treatment-related 
changes in bradykinesia and rigidity, whereas other aspects of speech improved independently 
of changes in motor performances. In summary, speech may be a valuable marker of disease 
progression and treatment efficacy in PD. 
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SUMMARY  
 
Parkinson’s disease (PD) is a neurological illness which caused impaired motor skills 
such as resting tremor, bradykinesia, muscular rigidity, and postural instability. In addition, 
many patients with PD develop non-motor symptoms such as disorders of mood, behaviour, 
thinking, and cognition and a distinctive alteration of speech characterized as hypokinetic 
dysarthria.  Parkinsonian dysarthria, in turn, results from a multidimensional impairment of 
respiration, phonation, articulation, and prosody. While the evidence of voice and speech 
disorders in the various severity levels of PD have been well documented, little is known 
about the early stages of PD, where the progression of speech is not influenced by medication. 
The overall aim of this DISSERTATION is to explore voice and speech disorders in early 
Parkinson’s disease using innovative methods of acoustic analysis. 
The DISSERTATION is presented as a collection of papers which can be associated with 
two main themes: 1) the design of novel acoustic measures and statistical methods for the 
identification of voice and speech disorders in PD, and 2) provision of more insights into 
understanding of the pathophysiological mechanisms responsible for the progression of 
parkinsonian speech impairment. The individual papers are devoted to the design of acoustic 
speech measurements, characterization of vocal impairment in PD, identification of speech 
disorders as early marker of PD, vowel articulation in PD, and longitudinal effects of 
dopaminergic treatment in PD.  
In the course of this DISSERTATION, a unique database of de novo patients with PD 
was recorded and re-tested one to two years after the introduction of dopaminergic therapy. 
The thesis provides a number of acoustic characteristics and statistical analysis for evaluation 
of the extent of vocal impairment and effect of treatment in PD. The general findings 
indicated deteriorated speech performance in the course of PD and reduction in speech 
impairment after the introduction of pharmacotherapy. The results of the DISSERTATION may 
be helpful in diagnosis of the disease, classifying the severity of disease, monitoring 
treatment, providing feedback in therapy, and offering support for therapists in the evaluation. 
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RÉSUMÉ   
 
Parkinsonova nemoc (PN) je neurologické onemocnění, které způsobuje zhoršení 
motorických příznaků, mezi něž patří klidový třes končetin, svalová ztuhlost, bradikineze a 
posturální poruchy. U většiny pacientů se v průběhu nemoci též rozvinou nemotorické 
příznaky, mezi něž patří poruchy nálady, chování, myšlení a také zhoršení řeči označováno 
jako hypokinetická dysartrie. Tato dysartrie je charakteristická zhoršením řeči ve 
všech oblastech včetně respirace, fonace, artikulace a prozodie. Přestože hlasové a řečové 
poruchy v různých stádiích PN jsou již dobře zdokumentovány, málo je známo o brzkých 
stádiích PN, kde zhoršení řeči není ovlivněno nasazením medikace. Hlavním cílem 
DIZERTACE bylo využití nových metod akustických analýz při hodnocení hlasových a 
řečových poruch u pacientů v brzkých stádiích PN. 
 DIZERTACE je prezentována jako soubor prací, které se vztahují ke dvěma hlavním 
tématům: 1) návrh nových akustických měření a statistických metod pro objektivní hodnocení 
poruch hlasu a řeči u PN a 2) porozumění problematice patofyziologických mechanizmů 
zodpovědných za progresi zhoršení řeči u PN. Jednotlivé publikace se zabývají těmito tématy: 
návrh nových akustických měření řeči, klasifikace řečových poruch u PN, využití řečových 
poruch jako „biomarkeru“ v brzkých stádiích nemoci, artikulace samohlásek u pacientů s PN 
a dlouhodobé efekty dopaminergní léčby PN. 
 V rámci dizertace byla nahrána unikátní databáze pacientů v brzkých stádiích PN před 
nasazením medikace. Tito pacienti byly zároveň retestováni po 1 až 2 letech léčby. Tato 
DIZERTACE nabízí množství akustických měření a statistických analýz pro hodnocení míry 
zhoršení hlasového projevu a efektu léčby u PN. Obecné nálezy indikují zhoršení řečového 
projevu pacientů s PN ve srovnání se zdravou populací a zlepšení řeči po nasazení léčby. 
Výsledky DIZERTACE mohou být využity při diagnostice nemoci, stanovení stádia nemoci, 
monitoringu efektů léčby a jako zpětná vazba při logopedické terapii. 
 
